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Abstract
Amyloids are aggregations of misfolded protein, which creates fibrillary struc-
tures. Unlike normally folded proteins, misfolded fibrils are insoluble and deposited 
extracellularly or intracellularly. The pathologic mechanism is still unclear, but 
resultant toxic oligomers within the tissue are known to damage the tissue via 
aberrant protein interactions. This condition has been known as amyloidosis. 
Different kinds of amyloid protein may cause similar or different clinical signs and 
symptoms, largely depending on the target organ it is deposited. However, because 
treatments and prognoses of each type are different drastically, it is critical to 
distinguish them and determine the specific type of amyloidosis. The confirmation 
and typing of amyloid heavily depend on pathologic examination of tissue. The 
gold standard method for the former is a Congo red staining and birefringence 
under polarized microscopy. The conventional way for the latter is immunohis-
tochemistry (IHC), where most of the amyloid types can be classified. However, 
electron microscopy, mass spectrometry, or other molecular methods are required 
for typing some amyloids that are difficult to identify through IHC. In this chapter, 
we will describe basic concepts of amyloidosis and pathologic findings of amyloid 
deposition, including atypical structural deposition. Furthermore, we will review 
methodologies for amyloid typing briefly.
Keywords: amyloid, amyloidosis, immunohistochemistry, molecular diagnosis, 
immunoelectron microscopy, atypical amyloid feature
1. Introduction
Amyloids are an aggregation of misfolded protein that creates fibrillary struc-
tures for various causes including hereditary or de novo mutations of the proteins 
and errors in the normal folding processes. This abnormally misfolded protein can 
aggregate into insoluble polymers or develop resistance against proteolysis. As a 
result, amyloid is deposited extracellularly or intracellularly within the tissue, caus-
ing tissue damage. This condition is called amyloidosis.
More than 90% of amyloid deposition is composed of protein fibrils, and the 
remainder of the deposition is proteoglycans, glycoproteins, or serum amyloid P 
components. Because more than 30 previously described species of amyloid protein 
share the same fibril structure, they may look similar when they are deposited 
within an organ. The structure of amyloid is observed by electron microscopy 
showing fibrils with a diameter of approximately 7.5–10 nm. Furthermore, 
β-pleated sheet structures within the fibrils were shown by X-ray crystallography 
and infrared spectroscopy.
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Depending on the chemical nature and the origin of the amyloid, each amyloid 
type has a tendency to be deposited in certain tissue or organ. However, the clinical 
signs and symptoms of different types can be remarkably similar when those types 
of amyloid are deposited within the same organ. Moreover, the deposited amyloid 
will show the same bright pink homogeneous amorphous materials when the 
affected organ is examined microscopically. This can be confirmed by apple-green 
birefringence on Congo red stain with polarization and fluorescence microscopy. 
Even if they have a similar morphologic appearance and similar clinical pictures, 
the treatment and prognosis vary significantly according to the type of amyloid. 
Thus, distinguishing the amyloid type is essential.
2. Molecular pathogenesis
The mechanisms of amyloidogenesis of each protein are quite variable and 
involve different overlapping mechanisms and environmental factors. The four 
recurring themes include intrinsic amyloidogenic tendency, increased concentra-
tion, altered proteolytic cleavage, and genetic mutation.
Several indigenous proteins have an innate tendency to fold into amyloid 
structure. Such proteins include transthyretin (TTR) and atrial natriuretic peptide 
(ANF). The former can deposit in the heart, joint, and other organs in the elderly, 
even without genetic mutations, and cause wild-type TTR amyloidosis (wtATTR) 
(formerly, senile systemic amyloidosis). In contrary to transthyretin, which is 
deposited in both the atria and ventricle, ANF deposits selectively in the atria and 
causes isolated atrial amyloidosis (IAA). This condition is also more common 
among the elderly and associated with atrial fibrillation. Other intrinsically prone 
proteins include apolipoproteins A-I, A-IV, and E and serum amyloid protein (SAP), 
which are incorporated in other forms of amyloid plaques nonspecifically.
Interestingly, exogenous proteins that have an amyloidogenic property can 
also cause amyloidosis. Two peptide drugs, insulin and enfuvirtide, have recently 
been described to cause localized amyloidosis [1]. Both drugs are injected subcu-
taneously, and the drug polypeptides may aggregate into amyloid fibril forming 
a localized amyloidoma. The amyloid fibrils are composed of the drug peptides 
themselves, which was confirmed by mass spectrometry. This pharmaceutical 
amyloidosis is an important differential diagnosis in a patient who presents with 
abdominal nodules and has been on insulin or enfuvirtide therapy.
Another contributing factor is persistently high concentrations of amyloidogenic 
proteins. Such elevated concentrations make it easier for the proteins to deposit and 
form a nidus for fibril extension and stabilization. These high levels can be achieved 
by either overproduction or undersecretion. For instance, SAP expression is greatly 
increased under inflammatory conditions, where the protein can aggregate to cause 
AA amyloidosis. Another example is dialysis-associated amyloidosis (Aβ2M), 
where β-2 microglobulin (β2M) level is increased in patients with end-stage renal 
disease due to ineffective elimination.
Amyloidosis caused by altered proteolytic cleavage is classically exemplified by 
Alzheimer’s disease, in which amyloid-β precursor protein (AβPP) forms neuritic 
plaques. When AβPP is cleaved by β- and γ-secretases rather than normal α- and 
γ-secretases, a highly amyloidogenic and neurotoxic oligomer Aβ is produced. The Aβ is 
believed to cause cellular dysfunction and neurodegeneration in Alzheimer’s disease.
Lastly, genetic mutations of proteins can form amyloid fibrils by one or more 
mechanisms previously mentioned. These alterations may involve either gene 
overexpression or structural changes. The former promotes amyloidogenesis 
by increased concentrations and the latter by either conferring amyloidogenic 
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instability to the protein or making the protein subject to amyloidogenic proteolytic 
cleavage. One important example is duplication or triplication of the SNCA gene, 
which results in increased production of the gene product α-synuclein. It aggre-
gates into toxic oligomer and amyloid plaques (Lewy body) and causes familial 
Parkinson’s disease. In hereditary transthyretin amyloidosis (hereditary 
ATTR), more than 130 mutations in TTR gene induce further instability to intrinsi-
cally unstable transthyretin and result in amyloid deposition in the heart, kidney, 
and peripheral nerves. Another interesting kind of mutation that can potentially 
produce amyloid by altered proteolytic cleavage involves gelsolin protein. Several 
mutations of gelsolin make the protein vulnerable to cleavage by furin, a ubiquitous 
protein convertase, producing amyloidogenic fragment C68 and causing hereditary 
familial amyloidosis of Finnish type.
Although different mechanisms are shown to be involved in amyloidogenesis, how 
some amyloid fibrils are deposited selectively in certain organs is not well known. In 
localized amyloidosis, the location of amyloid deposition may be related to the tissue 
where the amyloid protein is originated. For instance, islet amyloid polypeptide (IAPP 
or amylin) is an amyloidogenic peptide with physiologic roles in glucose regulation 
and secreted along with insulin by Langerhans islet cells. In type 2 diabetes and 
insulinoma, IAPP is deposited only in the islet of Langerhans, not exocrine pancreas. 
Other factors that may explain organotropism of amyloid fibrils include physiochemi-
cal environment and extracellular matrix. In dialysis-associated amyloidosis, β2m 
deposition in joint and bone tissue may be explained by the affinity of β2m for col-
lagen, enhanced fibril extension by glycosaminoglycans such as heparan sulfate and 
bone resorption and nidus formation by proinflammatory cytokines and acidosis.
Another unsettled issue is how amyloid formation can damage the target tissue. 
Extracellular deposition of amyloid fibrils itself may disrupt the organ integrity 
as in cerebral amyloid angiopathy (CAA), where Aβ is deposited in the walls of 
meningeal or cortical vessels, weakens the vessel, and leads to lobar hemorrhage. 
However, available evidence indicates that the primary mechanism of tissue damage 
in the majority of amyloidosis involves toxic oligomers rather than mature amy-
loid fibrils themselves. Despite various cellular defensive mechanisms to prevent 
proteins from misfolding like molecular chaperones and cochaperones, ubiquitin-
protease pathway, and autophagy, such “proteostasis” machineries can be over-
whelmed by mechanisms mentioned above. The resultant misfolded oligomers may 
exhibit hydrophobic residues that are normally buried inside the normal quaternary 
structure of the protein, and they seem to induce aberrant interactions with other 
proteins, triggering unfolded protein response, cell death, inflammation, and other 
pathways of cell injury. Moreover, these toxic oligomers seem to “spread” to the 
surrounding tissue in a prion-like manner, further propagating cell injury.
3. Major types of amyloidosis
The most recent classification of amyloidosis has been published by the 
Nomenclature Committee of the International Society of Amyloidosis (ISA) 
in 2016. The classification listed 36 different extracellular fibril proteins seen 
in humans and animals, whose sequence is identified unequivocally (Table 1). 
According to this scheme, amyloid proteins can be broadly divided into systemic 
or localized in relation to the extent of organ involved by the condition. Systemic 
forms of amyloidosis are common and may result in serious clinical conse-
quences, while localized forms tend to be less common and clinically indolent 
unless they involve critical organs such as CNS. Therefore, the distinction 
between the two is important.
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Table 1. 
Amyloid fibril protein classification and associated disease.
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Exhaustive review of every subtype is beyond the scope of this chapter. The more 
common and clinically important types of amyloid protein are described below.
3.1 Amyloid light chain (AL) protein
AL type amyloid is the most common amyloid in the United States. The AL chain 
is a clonal immunoglobulin light chain or light chain fragment, which is produced 
by the uncontrolled productions of antibodies by plasma cells. Lambda (λ) type 
(ALλ) is more common than kappa (κ) type (ALκ) light chain. This type of amyloi-
dosis is related to monoclonal plasma cell disorders, especially multiple myeloma or 
other B-lymphocyte-related disorders. If we cannot determine AL type amyloidosis 
to a certain disease, it is categorized as primary amyloidosis. Even if we cannot dem-
onstrate a specific disease to AL type amyloidosis, we still see monoclonal plasma 
cell proliferation in these patients. In either case, we can find immunoglobulin or 
light chain within the serum or urine. The most commonly affected organ is the 
kidney. The heart, peripheral nervous system, gastrointestinal tract, and respira-
tory tract can also be affected. A localized form of AL type amyloid can be seen in 
the gastrointestinal tract [2]. Amyloid heavy chain (AH) is rarely reported but also 
associated with monoclonal plasma cell disorder [3].
3.2 Amyloid-associated type (AA) protein
AA type amyloidosis is the most common amyloid worldwide. AA type amyloid 
is an acute phase protein derived from SAP by proteolysis. AA type amyloid is 
made in the liver, bounds to high-density lipoprotein (HDL), and is associated with 
chronic inflammatory disorder. In the past, the primary cause was predominantly 
of infections such as tuberculosis and chronic osteomyelitis. Nowadays, with the 
development of antibiotics, the most common source of AA type amyloid has 
become noninfectious inflammatory conditions, such as rheumatoid arthritis 
or inflammatory bowel diseases including Crohn’s disease and ulcerative colitis. 
Typical organs of AA type amyloid deposition are the kidney, liver, and spleen. 
AA type amyloidosis is also related to hereditary amyloidosis, caused by familial 
Mediterranean fever inherited as an autosomal recessive pattern. This is an auto-
inflammatory disorder characterized by frequent fever and serosal inflammation. 
The main affected organ is the kidney, but other organs such as the heart, spleen, 
and gastrointestinal tract can be affected [4].
3.3 Transthyretin amyloid (ATTR) protein
TTR is a transport protein made in the liver and choroid plexus. TTR transfers 
thyroxin and retinol in the blood and cerebrospinal fluid. TTR proteins can be 
differentiated into wild type and mutant type. TTR wild-type amyloid is associ-
ated with systemic senile amyloidosis and mostly affects heart ventricles in elderly 
patients. In this population, a prevalence of monoclonal gammopathy of unde-
termined significance (MGUS) has been reported [5]. TTR mutant type protein is 
related to hereditary amyloidosis. TTR mutant type protein can affect commonly 
peripheral nerves and other organs including the heart and gastrointestinal tract. 
This is inherited as an autosomal dominant pattern. The clinical course of TTR 
mutant type is relatively faster than TTR wild type in terms of onset and progres-
sion. Also, treatment and prognosis of two types are different. Therefore, distin-
guishing two types in early stage is important.
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3.4 Dialysis-related amyloidosis (Aβ2M)
β2M is a light chain component of the major histocompatibility complex (MHC) 
class I molecules. It is found in patients on dialysis and is rarely seen in renal 
failure patients who have not undergone dialysis. Since β2M is catabolized in the 
kidney, this protein may accumulate in renal failure patients. Conventional dialysis 
membranes do not remove this protein, thus dialysis-related β2M deposits occur 
in dialysis patients. Deposits occur mostly in the carpal ligaments, synovium, and 
bone. Other organs such as the heart, gastrointestinal tract, liver, lungs, prostate, 
adrenal glands, and tongue can be affected. These days, we use polyamide high-flux 
membranes to remove β2M, resulting in a lower incidence of this type of amyloid.
3.5 Amyloid β (Aβ) protein
Aβ protein comes from the proteolysis of an amyloid precursor protein known 
as transmembrane glycoprotein and accumulates as plaque in the cerebral cortex 
and in the blood vessel. Deposits within the blood vessels cause CAA, which induces 
progressive cognitive decline and lobar hemorrhage. The most well-known disease 
related to Aβ is Alzheimer’s disease. Rarely, familial Alzheimer’s disease, which 
occurs in an autosomal dominant pattern, is seen. In addition, by about age 50, 
Down syndrome patients present with amyloid deposits in the brain similar to those 
of patients with Alzheimer’s disease. Furthermore, a very rare form of hereditary 
cerebral hemorrhage with amyloidosis occurring in an autosomal dominant pattern 
has been reported.
Clinical symptoms are mostly nonspecific and may include headache, general 
weakness, edema, and weight change. Symptoms may also depend on the location and 
amount of amyloid deposition. Amyloid deposition in the heart causes arrhythmia, 
heart failure, or abnormal electric rhythm. Amyloid in the kidney eventually induces 
renal failure with proteinuria and uremia. If amyloid deposits within the blood ves-
sels, it creates ischemic or hemorrhagic condition for the organ. Amyloid deposition 
also mimics arthritis and peripheral neuropathy. Within the brain, it causes cognitive 
and memory disorders seen in Alzheimer’s disease or prion diseases. Localized deposi-
tion in the gastrointestinal tract has nonspecific gastrointestinal symptoms, such as 
dyspepsia or diarrhea. Since clinical symptoms are nonspecific, and most of the amy-
loid types can cause similar clinical features in the same organ; the clinical approach to 
amyloidosis is very limited. Therefore, a pathologic diagnosis of amyloidosis is critical.
4. Pathologic findings
Amyloid deposition is seen in the same manner within the same tissue no matter 
what protein it contains, except in a few cases. Grossly, amyloidosis deposition can 
appear as nodules and organomegaly, and sometimes it can show a pale gray to 
waxy color change with firm consistency. Microscopically, bright pink amorphous 
material deposition in extracellular space is most commonly observed under con-
ventional hematoxylin–eosin stain. Peculiar intracellular and spheroid type amyloid 
depositions may be seen, but they are rare.
Since the adventitious discovery by Hans Hermann Bennhold in 1922, Congo 
red stain has been the gold standard of confirming the presence of amyloid protein. 
When properly stained, the amyloid imparts red, orange, or salmon pink color. 
The subsequent demonstration of apple-green birefringence confirms the diag-
nosis of amyloidosis. However, this two-step method still suffers low sensitivity, 
specificity and reproducibility and heavily depends on the interpretation of highly 
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experienced pathologists. For instance, aside from the inherent sampling error, 
negative birefringence on positive Congo red stain may result in a false-negative 
result, even if the stained material actually contains amyloid. This “polarization 
shadow” can be overcome by rotating the slide table, which may detect additional 
small amount of amyloid protein. The intensity of the stain is also significantly 
affected by the washing process in the staining protocol, resulting in low reproduc-
ibility and mandating the use of positive control tissue. In addition, Congo red also 
stains collagen, elastin, or even non-fibrillary materials such as eosinophils, further 
complicating the interpretation.
To overcome such limitations of Congo red stain, additional filters such as a 
fluorescein isothiocyanate (FITC) or Texas red filter can be used [6]. These filters 
can augment the weak signal from Congo red into red fluorescence, greatly improv-
ing the detection sensitivity. Additional fluorochrome dyes, such as thioflavin T, can 
also be recruited. The stain becomes highly fluorogenic only when they are bound 
to amyloid, which imparts a yellow-green fluorescence when it is examined under 
fluorescence microscopy. Because both fluorescence filters and dyes are not entirely 
specific for amyloid, they should be used as adjunct in the context of Congo red 
stain. In conclusion, the light microscopic diagnosis of amyloidosis pertains not 
only to the on–off signal but also to staining techniques, specimen alignment under 
polarized light, fluorescence microscopy, and experience of the pathologist.
Generally, histological features are similar throughout the organ, but there are 
still specific features for specific organs, as will be discussed below.
4.1 Heart
Heart amyloidosis is induced by various types of amyloid. AL type is the most 
common amyloid found in the heart, while wtATTR, which causes systemic senile 
amyloidosis, is the second most common amyloid in the heart. Mostly, gross features 
will be normal unless it is late-stage amyloidosis. Minimal to mild enlargement of the 
heart, along with pale and waxy changes on the external surface, can be seen. Within 
the heart, ventricular wall concentric thickening, including that of the septum, is seen. 
The epicardium, endocardium, and valves can show nodular deposits. Histologically, 
there is no definite pattern of amyloid deposition based on the type of amyloid, and 
it normally shows blight pink amorphous deposition, showing an infiltrative pattern 
within the interstitium. Expanding to the myocardium can cause atrophy of myocar-
dial muscle. Also, arteriolar deposition can be seen in AL amyloidosis. Depending on 
the site of deposition and amount of deposition, it can cause conduction abnormality 
inducing arrhythmia, restrictive cardiomyopathy, and heart failure.
4.2 Kidney
The kidney is the most common organ where amyloid deposits. Various types 
of amyloid deposits can occur, but AA and AL type amyloids are the most common 
amyloid types seen in the kidney. Grossly, the kidney is firm, pale, and waxy. The size 
can vary between normal, enlarged, or small; if amyloid deposits within the arteries 
or arterioles and causes ischemia, the kidney becomes small. Histologically, there 
is no type-specific pattern. Amorphous bright pink deposits are mostly seen in the 
mesangium and capillary wall (Figures 1 and 2). In addition, interstitial peritubular 
tissue, arteries, and arterioles can be affected. Capillary wall thickening and mesangial 
expansion are seen. Sometimes, amyloid deposits protrude to the basement membrane 
of glomerular capillaries, showing discontinuity of the membrane. Expansion of amy-
loid within the mesangium eventually causes capillary obstruction and renal failure. 
Proteinuria is a very common finding among patients with kidney amyloidosis.
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Figure 2. 
Mesangium deposition of amyloid in kidney, ALλ type in immunofluorescence.
4.3 Liver
The most common amyloid type in the liver is AL and leukocyte-derived chemo-
taxin 2 (LECT2) type [7]. LECT 2 type amyloid (ALECT2) deposition was relatively 
recently found within the kidney and first reported in 2008 [8]. LECT 2 is synthe-
sized in the liver and is a chemotaxin that attracts neutrophils. Grossly, appearance 
ranges from normal to moderate and massive hepatomegaly. Histologically, we can 
see bright pink amorphous deposition within the sinusoidal space and vessel in the 
portal tract. AL type tends to have a sinusoidal pattern and a vascular pattern in 
the portal tract, but AA type shows a vascular pattern within the portal tract [9] 
(Figures 3 and 4). A globular pattern in sinusoids has been reported in LECT 2 
hepatic amyloidosis [10]. Even if there are more specific patterns depending on the 
type, they are not accurate, and sometimes there are overlapping patterns. Thus, 
confirmation with a specific stain is important. Kupffer cells and Multinucleated 
giant cells can be seen near the amyloid deposition. If amyloid expands, it induces 
hepatocyte atrophy and replaces normal hepatic tissue, causing liver failure.
4.4 Spleen
The spleen is mostly affected by AL type with plasmacytoid lymphovascular 
proliferation. The spleen shows two distinct gross patterns which are sago spleen 
and lardaceous spleen. Sago spleen has a gray, waxy, nodular appearance and is 
mild to moderately enlarged, and histologically, white pulp (follicles) is affected. 
Figure 1. 
Mesangium depositions of homogeneously bright pink material in kidney, H&E stain.
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If amyloid deposits grow, they replace the white pulp. Lardaceous spleen shows 
a diffuse waxy appearance and moderate to marked enlargement. Histologically, 
amyloid deposition is seen within the splenic sinuses and blood vessels.
4.5 Brain
The most common amyloid we see in the brain is β-amyloid. β-amyloid accumu-
lates diffusely in the extracellular space of the cerebral cortex and is most commonly 
related to Alzheimer’s disease. Characteristically, we can appreciate numerous 
extracellular depositions of amyloid plaques within the cortex (Figure 5). Amyloid 
plaques show filamentous appearance and can be demonstrated with a Congo red 
and a silver stain and β-amyloid IHC. Some dense amyloid plaques are surrounded 
by dystrophic neurites, reactive astrocytes, and microglia. Additionally, β-amyloid 
Figure 3. 
Sinusoidal depositions of homogeneously bright pink material in liver, H&E stain.
Figure 4. 
Sinusoidal deposition of amyloid in liver, Congo red stain under Texas red filter.
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Figure 6. 
Spheroid type amyloid deposition in colonic submucosa, Congo red stain.
can deposit within small-to-medium-sized arteries in the superficial cortex and 
leptomeningeal space and causes cerebral amyloid angiopathy. Cerebral amyloid 
angiopathy causes recurrent lobar hemorrhage. Furthermore, most Alzheimer’s-
affected brains show cerebral amyloid angiopathy as well.
4.6 Other organs
In the tongue, nodular deposition is seen, causing macroglossia. Gastrointestinal 
tract deposition of amyloid is common with polyps or ulcerative lesions. In the late 
stage, the cut surface shows yellow and waxy mural thickening. Clinically, it can cause 
motility disorders or stricture. Not uncommonly, vessels in the gastrointestinal tract can 
have amyloid deposition. In the respiratory tract, grossly nodular appearance is seen, 
and histologically, such depositions can be divided into four patterns including tracheo-
bronchial, nodular parenchymal, diffuse alveolar septal, and lymphatic [11]. Skin depo-
sitions vary in size and shape, from papules to nodules and plaque. As an endocrine 
organ, the thyroid can present with goiter and is associated with medullary carcinoma. 
Localized nodular deposition in the bone causes amyloidoma. Inflammation including 
giant cell, lymphocyte, and spheroid structure has been reported [12]. Joint depositions 
are seen mimicking rheumatoid arthritis, but less synovial inflammation is seen. Bone 
marrow deposition is commonly seen in multiple myeloma patients. For patients on 
chronic dialysis, amyloid-related carpal tunnel has been seen.
Figure 5. 
Amyloid plaque seen in Alzheimer disease, β amyloid antibody in IHC.
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4.7 Atypical amyloid findings
Cases of intracellular amyloid deposition have been reported in few organs 
including cardiomyocytes, plasma cells, as well as the histiocytes and β cells of 
the pancreas [12–14]. Spheroid type (corpora amylacea-like) amyloid deposition 
is reported in pituitary adenoma, squamous cell carcinoma of the uterine cervix, 
and amyloidoma of the bone, jejunum, and colon [15–18]. One case of spheroid 
type amyloid deposition from our group in association with colon adenocarcinoma 
is identified [2] (Figures 6 and 7). Current hypothesis regarding spheroid type 
amyloid deposition is that during the process of amyloid removal by macrophages, 
amyloid is packed inside the macrophage, making spheroid formations that are 
extracted into the surrounding tissue [18].
5. Immunohistochemistry and immunoelectron microscopy
While the Congo red stain positivity and birefringence are the gold standard 
of confirming amyloidosis, they do not tell what type of amyloid is deposited. 
Considering managements and clinical outcomes vary drastically according to the 
types, further studies to identify the causative protein are critical. Clinicopathologic 
correlation cannot substitute for amyloid typing.
Immunohistochemistry (IHC) is the most commonly utilized method for 
subtyping amyloidosis. IHC takes advantage of relatively specific binding proper-
ties of antibodies against different types of amyloid fibrils to illuminate the amyloid 
protein in tissue. A panel of antibodies for more common types can subtype the 
majority of amyloidosis cases. Such antibodies include those against ALλ, ALκ, 
AHγ, ATTR, Aβ2M, and AFib (fibrinogen). The method has been widely used 
due to low cost, ease of use, rapid turnaround time, and formalin-fixed paraffin-
embedded (FFPE) section compatibility.
However, there is one important pitfall in IHC. Because of heterogeneity of 
amyloid fibrils, nonspecific staining is common, and this potentially complicates 
the interpretation. For instance, the antibody against Aλ is notorious for non-
specific staining of amyloid other than Aλ. This diagnostic pitfall mandates the 
use of multiple comparative IHC stains to separate the true diagnostic positivity 
from the nonspecific reaction. In comparative IHC, subtyping of amyloid is 
determined by the specific amyloid with the strongest immunohistochemical 
reactivity.
Figure 7. 
Spheroid type amyloid deposition in colonic submucosa, Congo red stain under polarizer filter.
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Although not as commonly utilized as IHC, electron microscopy (EM) is a pre-
ferred method over Congo red birefringence or IHC in some institutions due to ambi-
guity of these stains in the interpretation. EM can confirm or rule out amyloidosis by 
visualizing amyloid fibrils in tissue as non-branching fibers with an average diameter 
of 7.5–10 nm. Because these fibers are considerably thicker than collagen fibers in EM, 
this technique can avoid diagnosing collagen fibers as amyloid fibrils, which is com-
mon in Congo red stain due to birefringence of collagen fibers in abdominal fat biopsy.
Morphologic patterns of EM have been described in amyloidosis affecting 
certain organs. Selective deposition in mesangial matrix and basement membrane 
and subepithelial “spikes” or “spicules” under podocyte foot processes are seen in 
glomerular amyloidosis (Figure 8). Amyloid deposition in tubular basement mem-
brane, interstitial space, and vascular wall are observed in extraglomerular amyloid. 
However, such differences in distribution are not specific enough to indicate certain 
subtypes of amyloidosis.
Some authors may further utilize immunoelectron microscopy (IEM), in which 
immunogold stains—antibody probes conjugated with gold particles—for ALλ, 
ALκ, AA, and ATTR are used to subtype the amyloid fibril. These stains “decorate” 
the target amyloid fibers and can be seen as “beads” in the fibrillary matrix of 
amyloid. IEM can detect even small amounts of amyloid fibrils, at earlier stages of 
the disease. However, the processing deals with a very small piece of tissue and leads 
to a false-negative result due to the limited sampling, especially in cases where the 
amyloid deposits are focal. Another barrier is fixation, where architectural details 
are preserved by cross-linking, but at the same time loss of antigenicity may result 
from dehydration and embedding procedures. Therefore, alternative fixatives such 
as modified Karnovsky’s solution rather than conventional glutaraldehyde with 
different protocols are used for IEM examination.
6. Molecular diagnosis
Recent advances in MS-based proteomic analysis have revolutionized detecting 
and subtyping of amyloidosis. The analytic method has made it possible to detect 
and identify new kinds of amyloid fibrils as well as previously known ones in a 
given specimen without direct sequencing. One such example is ALECT2. As men-
tioned above, LECT2 is synthesized by the liver and released into the circulation 
Figure 8. 
Amyloid fibrils diameter of approximately 7.5–10 nm non branched fibers in kidney, EM.
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and has uncertain physiologic roles in the cartilage and liver. It has been shown that 
ALECT2 is one of the major causes of kidney and liver amyloidosis after AL and AA 
amyloidosis, especially among Hispanics. This major amyloidosis may have been 
unrecognized due to a relatively indolent clinical course and limited ethnic distribu-
tion. Because serum LECT2 levels are not elevated, and no mutations are found in 
LECT2 gene so far, ALECT2 might have been misdiagnosed as AL or AA amyloido-
sis and treated as such without MS-based analysis.
The MS-based proteomic analysis utilizes techniques like laser microdissec-
tion (LMD), high-performance liquid chromatography (HPLC), and a variety 
of computational database tools. Although earlier HPLC- and MS-based analysis 
suffered from lack of specificity due to heterogeneous nature of the specimen, LMD 
largely overcame such diagnostic inaccuracy. LMD deals with microscopic examina-
tion of the specimen, selection of a field of interest, and microdissection of the field 
using laser in an attempt to achieve pure amyloid plaques. The dissected specimen 
can be submitted for histochemistry, IHC, or MS analysis. For FFPE specimens, an 
extra step for protein release similar to antigen retrieval used in IHC is applied. The 
released proteins are treated with a proteolytic enzyme (most commonly trypsin), 
and the resultant digested peptide fragments are separated by HPLC and analyzed 
with MS. This analytic method is based on an assumption that each human protein 
has their unique tryptic fragmentation patterns, which serves as a “fingerprint” of 
the protein. The analysis involves a previously curated database on human proteins 
and a number of computational algorithms to predict the amino acid sequences of 
the proteins that are contained in a given specimen.
Although the LMD- and MS-based proteomic analysis has demonstrated 
great sensitivity and specificity, they have one major pitfall. Because MS-based 
proteomic analysis heavily depends on human protein databases available in 
public, new polymorphisms or mutations may not be listed in the databases and, 
thus, cannot be identified using the technique. In such situations, a separate 
workflow to compare the newly identified mutations against previously known 
variants is utilized.
7. Conclusion
Amyloidosis is characterized morphologically by amorphous deposition of 
amyloid within tissue. The deposition is caused by aggregation of misfolded 
protein. Any disruptive processes in protein homeostasis (proteinostasis) can cause 
such misfolding and aggregation. Although different species of amyloid protein 
have different organotropisms and physiochemical properties, they appear remark-
ably similar when deposited within the target tissue. Clinical signs and symptoms 
of different types are largely affected by the organ where the amyloid is deposited. 
However, different treatment modalities and clinical courses according to the type 
mandate the exact subtyping of amyloid.
The confirmation and subtyping of amyloidosis heavily depend on patho-
logic examination of abdominal fat, minor salivary gland, or target organs. The 
gold standard for confirmation of amyloidosis is Congophilia and birefringence. 
Additional modalities such as IHC, EM, and MS can help further subclassify the 
type of amyloidosis.
Lately, new types of amyloidosis have been identified by MS. Atypical structure 
of amyloid continues to be found in various organs. Contrary to the conventional 
definition of amyloid, such as extracellular amorphous deposition, intracellular and 
spherical structure amyloids have been discovered. In addition, novel mutations of 
the same protein have been shown to confer totally different clinical implications. 
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of the Creative Commons Attribution License (http://creativecommons.org/licenses/
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The accumulation of new histologic findings and molecular studies will be an 
important key to understanding the disease mechanisms and, further on, the treat-
ment of amyloid-associated diseases.
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